Cancer Trials: US FDA Expands Scenarios Where Placebo Design Needs Justification
Executive Summary
Sponsors should justify use of a placebo control when primary adverse event prophylaxis is required, there exists an available therapy, or when placebo is given as monotherapy, agency says in final guidance applicable to randomized controlled oncology trials.